| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
|
Cho, Byoung Chul
|
|
|
204 |
C |
p.
|
artikel
|
| 2 |
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
|
Facchinetti, Francesco
|
|
|
204 |
C |
p.
|
artikel
|
| 3 |
A Reply to comment on “Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study”
|
Ma, Zhanming
|
|
|
204 |
C |
p.
|
artikel
|
| 4 |
Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis
|
Nguyen, Mai Hanh
|
|
|
204 |
C |
p.
|
artikel
|
| 5 |
Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy
|
Yang, Gowoon
|
|
|
204 |
C |
p.
|
artikel
|
| 6 |
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer
|
Nomura, Shogo
|
|
|
204 |
C |
p.
|
artikel
|
| 7 |
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis
|
Lintas, C.
|
|
|
204 |
C |
p.
|
artikel
|
| 8 |
Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trial
|
Lee, Jang Ho
|
|
|
204 |
C |
p.
|
artikel
|
| 9 |
Comment on “Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study”
|
Zhang, Bin
|
|
|
204 |
C |
p.
|
artikel
|
| 10 |
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study
|
Serna-Blasco, Roberto
|
|
|
204 |
C |
p.
|
artikel
|
| 11 |
Contents
|
|
|
|
204 |
C |
p.
|
artikel
|
| 12 |
Corrigendum to “A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers” [Lung Cancer 199 (2025) 108060]
|
Thunnissen, Erik
|
|
|
204 |
C |
p.
|
artikel
|
| 13 |
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)
|
Önder, Arif Hakan
|
|
|
204 |
C |
p.
|
artikel
|
| 14 |
Early experience with PEF in the setting of recalcitrant stage IV lung cancer
|
Moore, William H.
|
|
|
204 |
C |
p.
|
artikel
|
| 15 |
EGFR mutation testing across the osimertinib clinical program
|
Murat-Onana, Marie Laure
|
|
|
204 |
C |
p.
|
artikel
|
| 16 |
Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study
|
Shirai, Yukina
|
|
|
204 |
C |
p.
|
artikel
|
| 17 |
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival
|
Eklund, Ella A.
|
|
|
204 |
C |
p.
|
artikel
|
| 18 |
Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy
|
Gourlay, Ewan
|
|
|
204 |
C |
p.
|
artikel
|
| 19 |
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer
|
Kakiuchi, Yosuke
|
|
|
204 |
C |
p.
|
artikel
|
| 20 |
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens
|
Sugai, Mayu
|
|
|
204 |
C |
p.
|
artikel
|
| 21 |
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma
|
Ruan, Zhaohui
|
|
|
204 |
C |
p.
|
artikel
|
| 22 |
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study
|
Okada, Asuka
|
|
|
204 |
C |
p.
|
artikel
|
| 23 |
It is premature to close the door on hippocampal avoidance in prophylactic cranial irradiation?
|
Lehrer, Eric J.
|
|
|
204 |
C |
p.
|
artikel
|
| 24 |
Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study
|
Yamada, Jun
|
|
|
204 |
C |
p.
|
artikel
|
| 25 |
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
|
Guckenberger, Matthias
|
|
|
204 |
C |
p.
|
artikel
|
| 26 |
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges
|
Chen, Tong
|
|
|
204 |
C |
p.
|
artikel
|
| 27 |
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
|
van der Wel, J.W.T.
|
|
|
204 |
C |
p.
|
artikel
|
| 28 |
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
|
Feng, Jamie
|
|
|
204 |
C |
p.
|
artikel
|
| 29 |
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
|
Crespi, Veronica
|
|
|
204 |
C |
p.
|
artikel
|
| 30 |
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
|
Wheatley-Price, Paul
|
|
|
204 |
C |
p.
|
artikel
|
| 31 |
RETRACTED: Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta‐analysis
|
Shao, Tianyu
|
|
|
204 |
C |
p.
|
artikel
|
| 32 |
Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study
|
Tanaka, Susumu
|
|
|
204 |
C |
p.
|
artikel
|
| 33 |
Therapeutic management of patients with advanced thymic malignancies: A review for clinicians
|
Pavese, Valeria
|
|
|
204 |
C |
p.
|
artikel
|
| 34 |
The safety of extended dosing pembrolizumab when compared to traditional dosing: A review and meta-analysis of retrospective studies
|
Sekar, Prasanth
|
|
|
204 |
C |
p.
|
artikel
|
| 35 |
Unusual relapse dynamics in EGFR-mutated lung adenocarcinoma uncovered by genomic profiling: Insights from a case report
|
Roma, Luca
|
|
|
204 |
C |
p.
|
artikel
|
| 36 |
Whole slide image-level classification of malignant effusion cytology using clustering-constrained attention multiple instance learning
|
Kim, Dongwoo
|
|
|
204 |
C |
p.
|
artikel
|
Tijdschrift beschrijving